Curasight AS (XSAT:CURAS) Cash-to-Debt : No Debt ⁽¹⁾ (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Curasight AS Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Curasight AS's cash to debt ratio for the quarter that ended in Sep. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Curasight AS could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Curasight AS's Cash-to-Debt or its related term are showing as below:

XSAT:CURAS' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 6 years, Curasight AS's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

XSAT:CURAS's Cash-to-Debt is ranked better than
99.87% of 1487 companies
in the Biotechnology industry
Industry Median: 6.4 vs XSAT:CURAS: No Debt

Curasight AS Cash-to-Debt Historical Data

The historical data trend for Curasight AS's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Curasight AS Cash-to-Debt Chart

Curasight AS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Curasight AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Curasight AS's Cash-to-Debt

For the Biotechnology subindustry, Curasight AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curasight AS's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curasight AS's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Curasight AS's Cash-to-Debt falls into.

Curasight AS Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Curasight AS's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Curasight AS had no debt ⁽¹⁾.

Curasight AS's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Curasight AS had no debt ⁽¹⁾.

Curasight AS (XSAT:CURAS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Curasight AS Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Curasight AS's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Curasight AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curasight AS (XSAT:CURAS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Kobenhavn N, Kobenhavn, DNK, DK-2200

Website

https://www.curasight.com

Curasight AS is a clinical-stage biotech company committed to improving both diagnosis and the treatment of certain types of cancer. The company is focused on exploiting Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor.

Curasight AS Headlines

No Headlines

Curasight AS (XSAT:CURAS) Cash-to-Debt : No Debt (1) (As of Sep. 2024)